Home > Research > Publications & Outputs > Xenotransplantation and risk
View graph of relations

Xenotransplantation and risk: regulating a developing biotechnology

Research output: Book/Report/ProceedingsBook

Published

Standard

Xenotransplantation and risk: regulating a developing biotechnology. / Fovargue, Sara.
Cambridge: Cambridge University Press, 2011. 306 p.

Research output: Book/Report/ProceedingsBook

Harvard

APA

Vancouver

Fovargue S. Xenotransplantation and risk: regulating a developing biotechnology. Cambridge: Cambridge University Press, 2011. 306 p.

Author

Fovargue, Sara. / Xenotransplantation and risk : regulating a developing biotechnology. Cambridge : Cambridge University Press, 2011. 306 p.

Bibtex

@book{98ef0fd71dba401186f4e7e1eb27877f,
title = "Xenotransplantation and risk: regulating a developing biotechnology",
abstract = "Some developing biotechnologies challenge accepted legal and ethical norms because of the risks they pose. Xenotransplantation (cross-species transplantation) may prolong life but may also harm the xeno-recipient and the public due to its potential to transmit infectious diseases. These transboundary diseases emphasise the global nature of advances in health care and highlight the difficulties of identifying, monitoring and regulating such risks and thereby protecting individual and public health. Xenotransplantation raises questions about how uncertainty and risk are understood and accepted, and exposes tensions between private benefit and public health. Where public health is at risk, a precautionary approach informed by the harm principle supports prioritising the latter, but the issues raised by genetically engineered solid organ xenotransplants have not, as yet, been sufficiently discussed. This must occur prior to their clinical introduction because of the necessary changes to accepted norms which are needed to appropriately safeguard individual and public health.",
author = "Sara Fovargue",
year = "2011",
month = nov,
day = "17",
language = "English",
isbn = "9780521195768",
publisher = "Cambridge University Press",

}

RIS

TY - BOOK

T1 - Xenotransplantation and risk

T2 - regulating a developing biotechnology

AU - Fovargue, Sara

PY - 2011/11/17

Y1 - 2011/11/17

N2 - Some developing biotechnologies challenge accepted legal and ethical norms because of the risks they pose. Xenotransplantation (cross-species transplantation) may prolong life but may also harm the xeno-recipient and the public due to its potential to transmit infectious diseases. These transboundary diseases emphasise the global nature of advances in health care and highlight the difficulties of identifying, monitoring and regulating such risks and thereby protecting individual and public health. Xenotransplantation raises questions about how uncertainty and risk are understood and accepted, and exposes tensions between private benefit and public health. Where public health is at risk, a precautionary approach informed by the harm principle supports prioritising the latter, but the issues raised by genetically engineered solid organ xenotransplants have not, as yet, been sufficiently discussed. This must occur prior to their clinical introduction because of the necessary changes to accepted norms which are needed to appropriately safeguard individual and public health.

AB - Some developing biotechnologies challenge accepted legal and ethical norms because of the risks they pose. Xenotransplantation (cross-species transplantation) may prolong life but may also harm the xeno-recipient and the public due to its potential to transmit infectious diseases. These transboundary diseases emphasise the global nature of advances in health care and highlight the difficulties of identifying, monitoring and regulating such risks and thereby protecting individual and public health. Xenotransplantation raises questions about how uncertainty and risk are understood and accepted, and exposes tensions between private benefit and public health. Where public health is at risk, a precautionary approach informed by the harm principle supports prioritising the latter, but the issues raised by genetically engineered solid organ xenotransplants have not, as yet, been sufficiently discussed. This must occur prior to their clinical introduction because of the necessary changes to accepted norms which are needed to appropriately safeguard individual and public health.

M3 - Book

SN - 9780521195768

BT - Xenotransplantation and risk

PB - Cambridge University Press

CY - Cambridge

ER -